Sign Out
Hypersensitivity to capecitabine, 5-FU or to any of the excipients of the product History of severe and unexpected reactions to fluoropyrimidine therapy.
Patients with known dihydropyrimidine dehydrogenase (DPD) deficiency.
Patients with severe renal impairment (creatinine clearance below 30 mL/min).
Patients with severe hepatic impairment.
Patients with severe leucopenia, neutropenia (neutrophil counts <1.5 x 109/L), or thrombocytopenia (thrombocyte counts <100 x 109/L).
Treatment with sorivudine or its chemically related analogues, such as brivudine.
Pregnant or breastfeeding women.
